Ranger banner image

Effortless Deliverability. Exceptional Outcomes.

Ranger Drug-Coated Balloon

Ranger™ drug-coated balloon is built on the physician-preferred Sterling™ 0.014”/0.018” balloon platform with a low entry profile

Next-generation technology

Ranger banner image

Delivers like nothing else. Ranger

Ranger™ DCB is built on the physician-preferred Sterling™ 0.014”/0.018” balloon platform with a low entry profile.1

Ranger DCB has a low tip entry profile with 0.014”/0.018” guidewire compatibility

Ranger DCB's low profile and tapered tip enables a smooth delivery with excellent trackability and navigation through alternative access sites.¹


Efficient drug transfer

TransPax™ (citrate ester + low dose paclitaxel) is a next-generation coating that enables highly efficient drug transfer into the lesion.²⁻⁴

EluviaInfographic showing TransPax is lipophilic and TransPax is hydrophobic.

Ranger DCB product details

Ranger DCB has a comprehensive matrix.

Ranger Matrix

Proprietary loading tool

Serves as the balloon and drug protector to help prevent drug loss during insertion and limit the physician’s exposure to the drug.

Ranger loading tool


*Kaplan-Meier Estimate. 88.4% Primary Patency in the COMPARE Head-to-Head RCT. 1-Year Results published in the European Heart Journal. doi.org/10.1093/eurheartj/ehaa049. 89.8% Primary Patency in the RANGER II SFA RCT. 1-Year Results published in JACC:CI. doi.org/10.1016/j.jcin.2021.03.021. 
**Gongora C, et al. Comparative Drug-Coated Balloon Study, JACC Cardiovasc Interv. 2015;doi.org/10.1016/j.jcin.2015.03.020. 
***The limit of quantification was defined as <1 ng/mL. At 1 hour, 11 of 12 patients had no measurable levels of paclitaxel in their bloodstream. At 3 hours, the 12th patient had no measurable levels of paclitaxel. RANGER II SFA PK Substudy. RANGER II SFA RCT 1-Year Results published in JACC:CI. doi.org/10.1016/j.jcin.2021.03.021.


1. Boston Scientific Data on File. Ranger Catheter Competitive Testing Report, 92517674. Measurements from 6 x 120 devices for Ranger DCB, Lutonix™ 035.
2. Sachar R, et al. RANGER II SFA PK Substudy. 2019.
3. Steiner S, et al. COMPARE: prospective, randomized, non-inferiority trial of high- vs. low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. Eur Heart J. 2020;41:2541–2552.
4. Sachar R, et al. RANGER II SFA Investigators. 1-year results from the RANGER II SFA randomized trial of the Ranger drugcoated balloon. JACC Cardiovasc Interv. 2021;10:1123–1133.

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.